Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 5
2006 1
2007 5
2008 1
2009 3
2010 7
2011 5
2012 7
2013 3
2014 6
2015 8
2016 3
2017 1
2018 1
2019 1
2020 1
2021 2
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report.
Mackie C, Arora S, Seo P, Moody R, Rege B, Pepin X, Heimbach T, Tannergren C, Mitra A, Suarez-Sharp S, Borges LN, Kijima S, Kotzagiorgis E, Malamatari M, Veerasingham S, Polli JE, Rullo G. Mackie C, et al. Mol Pharm. 2024 Apr 10. doi: 10.1021/acs.molpharmaceut.4c00202. Online ahead of print. Mol Pharm. 2024. PMID: 38600804 Review.
Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series.
McAllister M, Flanagan T, Cole S, Abend A, Kotzagiorgis E, Limberg J, Mead H, Mangas-Sanjuan V, Dickinson PA, Moir A, Pepin X, Zhou D, Tistaert C, Dokoumetzidis A, Anand O, Le Merdy M, Turner DB, Griffin BT, Darwich A, Dressman J, Mackie C. McAllister M, et al. Among authors: mackie c. Pharmaceutics. 2022 May 7;14(5):1010. doi: 10.3390/pharmaceutics14051010. Pharmaceutics. 2022. PMID: 35631595 Free PMC article.
Characterisation of fasted state gastric and intestinal fluids collected from children.
Pawar G, Papadatou-Soulou E, Mason J, Muhammed R, Watson A, Cotter C, Abdallah M, Harrad S, Mackie C, Arien T, Inghelbrecht S, Batchelor H. Pawar G, et al. Among authors: mackie c. Eur J Pharm Biopharm. 2021 Jan;158:156-165. doi: 10.1016/j.ejpb.2020.11.010. Epub 2020 Nov 28. Eur J Pharm Biopharm. 2021. PMID: 33259897 Free article.
Oral bioavailability enhancement of flubendazole by developing nanofibrous solid dosage forms.
Vigh T, Démuth B, Balogh A, Galata DL, Van Assche I, Mackie C, Vialpando M, Van Hove B, Psathas P, Borbás E, Pataki H, Boeykens P, Marosi G, Verreck G, Nagy ZK. Vigh T, et al. Among authors: mackie c. Drug Dev Ind Pharm. 2017 Jul;43(7):1126-1133. doi: 10.1080/03639045.2017.1298121. Epub 2017 Mar 8. Drug Dev Ind Pharm. 2017. PMID: 28274133
Discovery of 8-Trifluoromethyl-3-cyclopropylmethyl-7-[(4-(2,4-difluorophenyl)-1-piperazinyl)methyl]-1,2,4-triazolo[4,3-a]pyridine (JNJ-46356479), a Selective and Orally Bioavailable mGlu2 Receptor Positive Allosteric Modulator (PAM).
Cid JM, Tresadern G, Vega JA, de Lucas AI, Del Cerro A, Matesanz E, Linares ML, García A, Iturrino L, Pérez-Benito L, Macdonald GJ, Oehlrich D, Lavreysen H, Peeters L, Ceusters M, Ahnaou A, Drinkenburg W, Mackie C, Somers M, Trabanco AA. Cid JM, et al. Among authors: mackie c. J Med Chem. 2016 Sep 22;59(18):8495-507. doi: 10.1021/acs.jmedchem.6b00913. Epub 2016 Sep 9. J Med Chem. 2016. PMID: 27579727
Evaluation of Three Amorphous Drug Delivery Technologies to Improve the Oral Absorption of Flubendazole.
Vialpando M, Smulders S, Bone S, Jager C, Vodak D, Van Speybroeck M, Verheyen L, Backx K, Boeykens P, Brewster ME, Ceulemans J, Novoa de Armas H, Van Geel K, Kesselaers E, Hillewaert V, Lachau-Durand S, Meurs G, Psathas P, Van Hove B, Verreck G, Voets M, Weuts I, Mackie C. Vialpando M, et al. Among authors: mackie c. J Pharm Sci. 2016 Sep;105(9):2782-2793. doi: 10.1016/j.xphs.2016.03.003. Epub 2016 Apr 22. J Pharm Sci. 2016. PMID: 27113473 Free PMC article.
55 results